Compare ROC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROC | CRDF |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | 82 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.7M | 86.8M |
| IPO Year | N/A | 2012 |
| Metric | ROC | CRDF |
|---|---|---|
| Price | $4.51 | $0.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $9.00 | ★ $9.63 |
| AVG Volume (30 Days) | 51.3K | ★ 1.6M |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $3.71 | $0.76 |
| 52 Week High | $7.80 | $3.31 |
| Indicator | ROC | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 40.26 | 27.50 |
| Support Level | $3.71 | N/A |
| Resistance Level | $5.32 | $2.03 |
| Average True Range (ATR) | 0.36 | 0.07 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 9.26 | 7.93 |
Rank One Computing Corp is an American artificial intelligence company. It develops AI systems that analyze visual data to identify and interpret objects and activities. The company's focus is on biometric identity, digital forensics, and real-time video analytics. It uses the term 'Vision AI,' which is an operational AI built for accuracy, speed, and auditability. The company generates revenue from the sale of access to its software platforms, maintenance services, and professional services.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.